MIR Preclinical Services

MIR Preclinical Services is a contract research organization (CRO) that provides specialized preclinical services to the pharmaceutical and biotechnology industries. The company focuses on oncology and inflammation, utilizing advanced molecular imaging technologies such as PET, SPECT, CT, and MRI to evaluate drug efficacy and distribution. By combining imaging with traditional pharmacology, MIR offers unique insights into the mechanism of action and therapeutic potential of drug candidates. In 2011, the company was acquired by Charles River Laboratories, integrating its expertise into a broader suite of discovery and development services. Its facilities in Ann Arbor, Michigan, continue to serve as a hub for high-end preclinical imaging and pharmacology studies.